Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.60 |
| ▸ | ASF1A | Q9Y294 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21192738 | 1.00 | MAPT (0.65) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL21145646 | 0.91 | MAPT (0.61) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL684559 | 0.91 | MAPT (0.61) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL684649 | 0.89 | SIRT1 (0.67) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL12443277 | 0.88 | KMT2A (0.73) | MAPTSMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL684953 | 0.88 | SIRT1 (0.64) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL684648 | 0.88 | KDM1A (0.58) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL21192742 | 0.87 | MEN1 (0.78) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL684562 | 0.86 | MAPT (0.57) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL16181024 | 0.86 | ERN1 (0.49) | MAPTSMN1; SMN2MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9029403-B2 | Treatment of ovarian cancer with benzylidenebenzohydrazides | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140315959-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2014-10-23 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865901-B2 | Gain-of-function Bcl-2 inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2013071001-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011041737-A2 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MAPT 1762/4885SMN1; SMN2 595/4885MAPK1 2835/4885 |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, SOD3 | MAPT 1491/4885SMN1; SMN2 4107/4885MAPK1 3282/4885 |
| US-20120252839-A1 | GAIN-OF-FUNCTION BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | MAPT 3794/4885SMN1; SMN2 567/4885MAPK1 3645/4885 |
| US-20140315959-A1 | TREATMENT OF OVARIAN CANCER WITH BENZYLIDENEBENZOHYDRAZIDES | BRDT, BAX, BCL2 | MAPT 4837/4885SMN1; SMN2 4301/4885MAPK1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.